Skip to main content
. 2019 Aug 2;10(8):578. doi: 10.1038/s41419-019-1819-3

Fig. 5. Malignant cells treated with 8-MOP plus UVA light in vitro confer tumor-specific immunological protection upon inoculation in syngeneic immunocompetent hosts.

Fig. 5

a, b Tumor-free survival (TFS) of C57BL/6 mice upon inoculation of PBS (no vaccination) or B16-OVA cells subjected to repeated freeze/thawing (F/T) or exposed to 8-methoxypsoralen plus 4J UVA light (8-MOPA) and then cultured in control conditions for 24 h, or treated with 200 µM cisplatin (CDDP) for 24 h, followed (one week later) by the contralateral inoculation of living B16-OVA cells. Representative images (a) and quantitative results (b) are reported. n = 50 mice (8-MOPA), 50 mice (control), 25 mice (CDDP), 20 mice (F/T); ***p < 0.001 (Log-rank test), as compared to mice vaccinated with PBS. c Percentage of tumor-naive C57BL/6 mice and C57BL/6 mice pre-vaccinated with B16-OVA cells exposed to 8-MOPA and cultured in control conditions for 24 h developing tumors upon re-challenge with B16-OVA cells or MC38 cells. Quantitative results are reported. n = 5 mice per group; **p < 0.01, n.s., not significant (Log-rank test), as compared to tumor-naive mice. d TFS of C57BL/6 mice upon inoculation of PBS (no vaccination) or wild-type B16, YUMMER, or MC38 cells exposed to 8-MOPA and cultured in control conditions for 24 h, followed (one week later) by the contralateral inoculation of living B16, YUMMER or MC38 cells, respectively. Quantitative results are reported. n = 30 mice per group (B16), 5 mice per group (YUMMER), 10 mice per group (MC38); **p < 0.01, ***p < 0.001 (Log-rank test), as compared to mice vaccinated with PBS